Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kodai Kunisada
Observed name:
Kunisada, Kodai
Institutions:
Japanese Red Cross Medical Center,
National Cancer Center Hospital East
Observed institutions:
Japanese Red Cross Medical Center,
National Cancer Center Hospital East
ORCID:
0009-0004-3986-4233
Observed ORCID:
0009-0004-3986-4233
OpenAlex ID:
A5081389982
Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
International Journal of Hematology
·
7
PDF
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma
2025
·
Taku Kikuchi
, Miyu Watanabe
, et al.
·
Transplant Infectious Disease
·
6
Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies
2024
·
Taku Kikuchi
, Yuki Oda
, et al.
·
Hematological Oncology
·
4
PDF
Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Hematological Oncology
·
3
PDF
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies
2023
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Annals of Hematology
·
3
Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma
2026
·
Taku Kikuchi
, Ukyo Kondo
, et al.
·
Transplantation and Cellular Therapy
·
2
Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma: Two Case Reports
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Cureus
·
2
PDF
Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Acta Haematologica
·
2
Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment
2024
·
Takafumi Tsushima
, Nobue Sato
, et al.
·
eJHaem
·
2
PDF
Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab
2025
·
Ukyo Kondo
, Taku Kikuchi
, et al.
·
eJHaem
·
1
PDF
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?
2025
·
Taku Kikuchi
, Ukyo Kondo
, et al.
·
Blood Advances
·
1
PDF
Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Hematological Oncology
·
1
Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting
2024
·
Taku Kikuchi
, Nobuhiro Tsukada
, et al.
·
Annals of Hematology
·
1
[Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
2022
·
Kodai Kunisada
, Akihito Matsuoka
, et al.
·
PubMed
·
1
Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma
2026
·
Taku Kikuchi
, Moe Nomura-Yogo
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience
2026
·
Taku Kikuchi
, Ukyo Kondo
, et al.
·
British Journal of Haematology
Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study
2026
·
Nobue Sato
, Yong-Mei Guo
, et al.
·
Cureus
PDF
Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen
2026
·
Taku Kikuchi
, Ukyo Kondo
, et al.
·
Amyloid
Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen
2026
·
Kikuchi, Taku
, Kondo, Ukyo
, et al.
·
Figshare
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS
2025
·
Taku Kikuchi
, Shotaro Sugita
, et al.
·
International Journal of Hematology
Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab
2025
·
Ukyo Kondo
, Taku Kikuchi
, et al.
·
Blood
[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis].
2025
·
Kodai Kunisada
, Mizuki Ogura
, et al.
·
PubMed
[Successful management of cardiac arrest due to cytokine release syndrome following chimeric antigen receptor T-cell therapy for multiple myeloma].
2025
·
Yuki Oda
, Kota Sato
, et al.
·
PubMed
Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab
2024
·
Taku Kikuchi
, Kodai Kunisada
, et al.
·
Cureus
PDF
Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis
2024
·
Kodai Kunisada
, Taku Kikuchi
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
31
Citation count:
36
H-index:
3
I10-index:
Year
Topic
Type